Medication therapy management: Opportunities and barriers
November 22nd 2004Medication therapy management services (MTMS), as outlined in the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA 2003), is likely to have a significant impact on pharmacy practice, Jannet Carmichael, Pharm.D., told attendees at the American College of Clinical Pharmacy annual meeting, held last month in Dallas. She is PBM manager at VISN 21 Health Care Services at the VA Sierra Pacific Network in Reno.
ASHP survey shows pharmacy leadership crisis looming
November 22nd 2004A severe shortage of pharmacy directors and assistant directors could put a damper on progress made by pharmacists at a time when they are poised to take commanding ownership of medication and patient-safety leadership positions in hospitals.
Hospital pharmacy worries over workforce supply
November 22nd 2004A workforce shortage combined with federal government funding cutbacks may complicate the lives of an incoming generation of pharmacists. So claimed two of the profession's topsiders at an ASHP leadership conference, held recently in Chicago.
JCAHO issues sentinel alert over inadequate anesthesia
November 22nd 2004Anesthesia awareness-the unexpected cognizance that occurs when anesthesia lightens during surgery-is the subject of a recent Sentinel Event Alert issued by the Joint Commission on Accreditation of Healthcare Organizations. Forty-eight percent of patients who experience awareness report auditory recollections, 48% report being unable to breathe, and 28% report pain-without being able to communicate this to the surgical team.
Skin pigmentation disorders: More than just cosmetic?
November 22nd 2004The American Academy of Dermatology estimates that five million to six million Americans will at some point experience a skin pigmentation condition. Of all these disorders, vitiligo has the most devastating effects on the patient's psychosocial and emotional well-being. Other conditions, such as melasma and solar lentigines, may have less disabling psychological effects, but they are not inconsequential. Raising awareness of these skin disorders was recently discussed at a Galderma-sponsored luncheon in New York City.
Infertility agent targets profound LH deficiency
November 22nd 2004Remember when one of the first drugs used to stimulate fertility was obtained from the urine of postmenopausal nuns, actually in the Vatican? The drug, if you recall, was Pergonal, and it was a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
GMDC to retailers: Pay heed to women shoppers
November 8th 2004There are many strategies that retailers can implement to better serve women shoppers, particularly in the sanitary protection, skin care, and cosmetics categories. This recommendation comes from the recently released Merchandising for Success study by the General Merchandise Distributors Council (GMDC) Educational Foundation.
Pharmacists can help stop counterfeit drugs
November 8th 2004Busy behind the pharmacy counter, many pharmacists may think they can't enlist in the fight against increasingly bold and sophisticated counterfeiters, but there are ways they can make it tougher for fake medications to reach their patients, according to industry experts.
First in new class for insomnia
November 8th 2004For the estimated 70 million people in the United States suffering from insomnia the availability of a novel treatment option would be welcome relief. Takeda, which recently submitted an NDA to the FDA, hopes its compound, ramelteon (TAK-375), will meet that challenge. Ramelteon is a novel selective melatonin (ML-1) receptor antagonist developed by Takeda for the treatment of insomnia. According to the firm, this is the first new mechanism of action to be developed in 35 years in the area of sleep research.
First in new class for insomnia
November 8th 2004For the estimated 70 million people in the United States suffering from insomnia the availability of a novel treatment option would be welcome relief. Takeda, which recently submitted an NDA to the FDA, hopes its compound, ramelteon (TAK-375), will meet that challenge. Ramelteon is a novel selective melatonin (ML-1) receptor antagonist developed by Takeda for the treatment of insomnia. According to the firm, this is the first new mechanism of action to be developed in 35 years in the area of sleep research.
Surgeon General's osteoporosis report wins wide support
November 8th 2004Reaction from healthcare practitioners to the U.S. Surgeon General's recent report on fractures related to osteoporosis has been swift and generally supportive of the report's conclusions. The landmark report stated that, by 2020, one-half of all Americans older than 50 will be at increased risk for fractures from osteoporosis and low bone mass if greater measures aren't taken to improve overall bone health.
First immediate-release PPI hits pharmacy shelves
November 8th 2004For well over a decade, proton pump inhibitors (PPIs) have been considered the first-line treatment for gastroesophageal reflux disease, or GERD. In 2003, U.S. sales of the five delayed-release PPI brands totaled $12.9 billion, with total U.S. prescriptions for PPIs growing 10%, from 86.3 million in 2002 to 95.2 million in 2003, according to IMS Health.
Diabetes care: Drugstores the clear choice for patients
November 8th 2004According to Information Resources Inc. (IRI), sales of Home Health Care Kits, including blood glucose monitors, grew 2.7% to $677 million over the 52-week period ending April 19, 2004. Simultaneously, all outlets--drug, food, and mass-merchandising--posted sales gains. Increasing 6%, food outlets outpaced the other two retailers.
Growth hormone use: How short is too short?
November 8th 2004The Food & Drug Administration has created a conundrum for short children, their parents, pharmacists, and pediatricians. The agency approved the use of human growth hormone (somatropin recombinant, Humatrope, Eli Lilly) in June 2003 to treat idiopathic shortness. But instead of clarifying which children should be treated for short stature, the FDA may have opened the door to abuse.
New extended-release opioid treats persistent pain
October 25th 2004Tens of millions of people in the United States are affected by pain, which is associated with a variety of effects that can destroy the pain sufferer's quality of life. Treating and controlling pain is a primary concern for all members of a healthcare team. Despite the attention given to the association of opioids with drug abuse, consensus statements from experts support the use of these products to treat chronic pain. And soon a new opioid will be available for sufferers of chronic, persistent pain.
USP Drug Safety Review: Errors involving PCA pumps
October 25th 2004To prevent the administration of excessive amounts of analgesia medication, patient-controlled analgesia (PCA) pumps offer several safety features (e.g., a "lockout interval" specifies both the minimum amount of time between each dose and an established maximum allowable amount of drug during a predefined time period). Despite such advantages, medication errors involving PCA pumps continue to occur.
JCAHO studying how hospitals help patients stop smoking
October 25th 2004The Joint Commission on Accreditation of Healthcare Organizations has begun a study to examine the types of counseling hospitals offer patients to help them quit smoking. The goal of the study is to identify and evaluate strategies hospitals can use to help patients who smoke to kick the habit.
JCAHO sets new patient safety goals for 2005
October 25th 2004Institutional pharmacists should get ready for more intensive scrutiny of their operations next year. Half of the 2005 National Patient Safety Goals (NPSGs) set by the Joint Commission on Accreditation of Healthcare Organizations are directly related to pharmacy.